• Egetis Therapeutics

  Participated · Equity · Oct 2025

  Egetis Therapeutics is a publicly traded company on Nasdaq Stockholm. The firm recently strengthened its balance sheet through an oversubscribed directed share issue that brought in approximately SEK 183 million before transaction costs. In the transaction, the company issued 35,923,812 new common shares at a subscription price of SEK 5.10 per share, reflecting a 4.9 percent discount to the closing price on 2 October 2025. The capital raise attracted both Swedish and international investors, including Frazier Life Sciences, Invus, Petrichor, Woodline Partners LP, Fjärde AP-fonden and Linc AB. Proceeds from the financing increase the company’s financial flexibility for its ongoing corporate activities. The oversubscription signals strong market confidence in the company and its future prospects.

• Akiram Therapeutics

  Participated · Equity · Jan 2023

  Akiram Therapeutics is developing a targeted radioimmunotherapy that combines the company’s proprietary antibody with the radioactive compound lutetium‑177. Its lead candidate’s first indication is anaplastic thyroid cancer, where extensive preclinical studies showed tumours disappearing entirely after a single treatment in animal models. The company believes the candidate has potential to be first‑in‑class and to qualify as an orphan drug. Akiram also sees clinical potential in other thyroid and head‑and‑neck cancers. The team includes leading experts in radiation science, precision oncology and drug development, and is led by founder and CEO Marika Nestor. Recent financing gives the company resources to accelerate development and prepare for clinical trials, including an intended phase I study.

No current team members are available.